I still can't figure out how CT:VQ is ever going to generate anything other than a huge amount of noise. The original selling point for 4Dx was that you could just layer their software (remember the SaaS story?) on top of cheap old fluoroscopy. No CT scanning, no new scanner. That seems to have been wishful thinking. Now it is contrast free angiography and ventilation imaging to diagnose PE? I just don't get how the resolution could be sufficient. Anyway. Meanwhile CYC makes the best V imaging component on the market. I don't know if it will ever seriously take ctpa market share (CTs are just everywhere and easy to order and pretty easy to interpret for pe) but capturing the existing v/q space in the US, Canada and Europe is a decent objective. There is a lot of chat about small airways disease in asthma and prism in smoking related lung disease so we do need other measures apart from spirometry. V/q makes a bit of sense here. I don't think this company is going to transform healthcare or anything ambitious like that, but it does seem likely to generate pretty consistent and solid revenue once the initial grind upwards gets momentum. And MC feels way off based on that.
imo, dyor, gltah
CYC Price at posting:
$1.67 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)